<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03906578</url>
  </required_header>
  <id_info>
    <org_study_id>HYPRO</org_study_id>
    <nct_id>NCT03906578</nct_id>
  </id_info>
  <brief_title>Effects of a Probiotic in Hypertension</brief_title>
  <acronym>HYPRO</acronym>
  <official_title>Effect of a Probiotic on Blood Pressure in Low-to-moderate Risk Grade 1 Hypertension - a Randomized Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      High blood pressure is a major risk factor for cardiovascular events, including stroke, heart
      and kidney failure. Typical anti-hypertensive drugs target vessels, the kidneys or the heart.
      Here we propose a randomized, placebo-controlled study to test the blood pressure-lowering
      effect of a probiotic in 110 patients with grade 1 hypertension. In addition, we will
      investigate glucose variability, fecal bacterial metabolome, peripheral blood effector T cell
      frequencies (%) and health-related quality of life.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 2, 2019</start_date>
  <completion_date type="Anticipated">September 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Nocturnal systolic blood pressure</measure>
    <time_frame>After 8 weeks compared to placebo and adjusted to baseline</time_frame>
    <description>Measured by 24h ABPM (mmHg)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Nocturnal diastolic blood pressure</measure>
    <time_frame>After 8 weeks compared to placebo and adjusted to baseline</time_frame>
    <description>Measured by 24h ABPM (mmHg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24h systolic blood pressure</measure>
    <time_frame>After 8 weeks compared to placebo and adjusted to baseline</time_frame>
    <description>Measured by 24h ABPM (mmHg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24h diastolic blood pressure</measure>
    <time_frame>After 8 weeks compared to placebo and adjusted to baseline</time_frame>
    <description>Measured by 24h ABPM (mmHg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Office systolic blood pressure</measure>
    <time_frame>After 8 weeks compared to placebo and adjusted to baseline</time_frame>
    <description>Mean of five consecutive blood pressure measurements (mmHg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Office diastolic blood pressure</measure>
    <time_frame>After 8 weeks compared to placebo and adjusted to baseline</time_frame>
    <description>Mean of five consecutive blood pressure measurements (mmHg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction of antihypertensive medication</measure>
    <time_frame>After 8 weeks compared to placebo and adjusted to baseline</time_frame>
    <description>Number and dosage of prescribed medication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose variability after standardized breakfasts</measure>
    <time_frame>After 8 weeks compared to placebo and adjusted to baseline</time_frame>
    <description>Measured by continuous glucose monitoring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gut microbiome</measure>
    <time_frame>After 8 weeks compared to placebo and adjusted to baseline</time_frame>
    <description>Change of fecal microbiome composition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolomics stool and serum</measure>
    <time_frame>After 8 weeks compared to placebo and adjusted to baseline</time_frame>
    <description>Change of fecal and serum metabolome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in immune cell phenotypes</measure>
    <time_frame>After 8 weeks compared to placebo and adjusted to baseline</time_frame>
    <description>Peripheral blood effector T cell frequencies (%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PROMIS-29 domain pain interference</measure>
    <time_frame>After 8 weeks compared to placebo and adjusted to baseline</time_frame>
    <description>Range 0-10 with 0 indicating no pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PROMIS-29 domain depression</measure>
    <time_frame>After 8 weeks compared to placebo and adjusted to baseline</time_frame>
    <description>Lower (better) T-score (mean 50, SD 10)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PROMIS-29 domain anxiety</measure>
    <time_frame>After 8 weeks compared to placebo and adjusted to baseline</time_frame>
    <description>Lower (better) T-score (mean 50, SD 10)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PROMIS-29 domain physical function</measure>
    <time_frame>After 8 weeks compared to placebo and adjusted to baseline</time_frame>
    <description>Higher (better) T-score (mean 50, SD 10)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PROMIS-29 domain fatigue</measure>
    <time_frame>After 8 weeks compared to placebo and adjusted to baseline</time_frame>
    <description>Lower (better) T-score (mean 50, SD 10)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PROMIS-29 domain sleep disturbance</measure>
    <time_frame>After 8 weeks compared to placebo and adjusted to baseline</time_frame>
    <description>Lower (better) T-score (mean 50, SD 10)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PROMIS-29 domain ability to participate in social roles and activities</measure>
    <time_frame>After 8 weeks compared to placebo and adjusted to baseline</time_frame>
    <description>Higher (better) T-score (mean 50, SD 10)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Probiotic</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Two sachets Vivomixx® containing 8 strains of life bacteria (9 x 10^11 CFU) in the evening for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Two sachets placebo in the evening for 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vivomixx®</intervention_name>
    <description>Microbiotic food supplement with L. paracasei, L. plantarum, L. acidophilus, L. delbrueckii, B. longum, B. infantis, B. breve, S. thermophilus</description>
    <arm_group_label>Probiotic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo with similar appearance to probiotic</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and postmenopausal women

          -  Treated or untreated grade 1 hypertension (resting office blood pressure &gt;140/90 mmHg)

          -  BMI 18.5 - 34.9 kg/m^2

        Exclusion Criteria:

          -  Secondary causes of hypertension

          -  Known target organ damage

          -  10 years cardiovascular risk score of &gt;20%

          -  Diabetes

          -  Established cardiovascular or renal disease

          -  Other serious diseases

          -  Recent use of antibiotics

          -  Specialized diets, e.g. use of probiotics
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anja Mähler, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charite University, Berlin, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dominik N. Müller, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Max Delbruck Center (MDC)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ralf Dechend, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charite University, Berlin, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anja Mähler, PhD</last_name>
    <phone>+49 30 450 540 323</phone>
    <email>anja.maehler@charite.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Experimental and Clinical Research Center</name>
      <address>
        <city>Berlin</city>
        <zip>13125</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anja Mähler, PhD</last_name>
      <phone>+49 30 450 540 323</phone>
      <email>anja.maehler@charite.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>April 5, 2019</study_first_submitted>
  <study_first_submitted_qc>April 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 8, 2019</study_first_posted>
  <last_update_submitted>September 3, 2019</last_update_submitted>
  <last_update_submitted_qc>September 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>Anja Maehler</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data that underlie the results of reported articles (text, tables, figures, supplemental data) will be shared after deidentification.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>Beginning 9 months and ending 36 months following article publication.</ipd_time_frame>
    <ipd_access_criteria>Researchers who provide a methodologically sound proposal.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

